Clinical stage biotechnology company X4 Pharmaceuticals revealed on Monday that Gary J Bridger, PhD has been appointed to its board of directors.
Dr Bridger currently serves as a board member of Aquinox Pharmaceuticals. Previously, he was a co-founder and chief scientific officer of AnorMED Inc, through its acquisition by Genzyme in 2007.
Earlier, Dr Bridger was a board member for Alder Biopharmaceuticals and had also served as executive vice president of Research and Development of Xenon Pharmaceuticals, as well as managing director at Five Corners Capital.
X4 Pharmaceuticals is currently developing novel therapeutics that are designed to improve immune cell trafficking to treat rare diseases and cancer. Its oral small molecule drug candidates antagonise the CXCR4 pathway, which plays a central role in immune surveillance. The company added that its most advanced product candidate is in a Phase 2/3 clinical trial in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease and is currently under investigation in multiple clinical trials in solid tumours.
Convergent Therapeutics names new chairman of board of directors
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Cardinal Health names new independent director
Micron Biomedical names new scientific advisor to CEO
MedPharm names new executive chairman
Armonica Technologies names new director
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Ardigen names new chief commercial officer
AbbVie names new chief executive officer
AMO Pharma collaborates with Population Health Research Institute for tideglusib clinical trial